Streetbeat News

Products Services

MRK

Merck and EyeBio have launched a Phase 2b/3 trial for Restoret™ (MK-3000) to treat diabetic macular edema. This trial follows promising results from earlier studies, marking a significant step in developing new treatments for retinal diseases.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:45 am

RIVN

TSLA

Former Tesla executive Rohan Patel predicts a decade of upheaval in the auto industry, emphasizing the need for efficiency and innovation over protectionist measures. Tesla CEO Elon Musk questions Rivian's financial reliance on Volkswagen amidst the latter's potential factory closures in Germany due to competitive pressures.

Portfolio Pulse from Anan Ashraf

September 04, 2024 | 10:41 am

KARS

NIO

PGJ

NIO Inc. shares are trading higher in the premarket session, driven by the company's expansion of battery swap stations in China. NIO added 40 new stations in August, with 35 being the latest fourth-generation models. The company aims to expand its network to cover over 2,300 counties by the end of 2025. Investors can gain exposure to NIO through ETFs like KraneShares Electric Vehicles and Future Mobility Index ETF (KARS) and Invesco Golden Dragon China ETF (PGJ).

Portfolio Pulse from Nabaparna Bhattacharya

September 04, 2024 | 10:32 am

IMUX

Immunic has enrolled the first patient in a Phase 2 trial of Vidofludimus Calcium (IMU-838) for treating post-COVID syndrome. This trial is investigator-sponsored and marks a significant step in exploring treatments for long-term COVID-19 effects.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:32 am

MYGN

Myriad Genetics has decided to discontinue the second part of a study due to significant disparities between the GeneSight group and the control group, which was deemed not viable.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:20 am

SOPH

SOPHiA GENETICS has launched a new generation of its SOPHiA DDMTM platform, which is expected to enhance data-driven medicine capabilities. This development could potentially impact the company's market position and attract investor interest.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:09 am

HRL

Hormel Foods Corp has revised its fiscal year 2024 financial outlook, lowering net sales expectations to $11.8B-$12.1B from $12.2B-$12.5B due to lower commodity markets and production disruptions. Adjusted EPS is now expected to be $1.57-$1.63, slightly narrowed from previous estimates.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:08 am

QH

Quhuo International and GET Holdings have formed a strategic partnership in Azerbaijan with electric vehicle dealer Volt Auto and mobility platform Bolt. This collaboration aims to enhance electric vehicle adoption and mobility services in the region.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:08 am

DGHI

Digihost reported a 30% increase in Bitcoin production in August 2024, with miners producing approximately 55 BTC compared to July.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:07 am

INCY

LLY

Eli Lilly and EVA Pharma have partnered to expand access to Baricitinib, a treatment for several conditions, to 20,000 people in 49 African countries by 2030. Baricitinib was discovered by Incyte and licensed to Lilly.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:06 am